Arginine vasopressin receptor antagonists (vaptans): Pharmacological tools and potential therapeutic agents

Drug Discovery Today

Volumn 15, Issue 19-20, 2010, Pages 826-841

  Veeraveedu, Punniyakoti T ^a,b   Palaniyandi, Suresh S ^a,c   Yamaguchi, Ken'ichi ^d   Komai, Yutaka ^b   Thandavarayan, Rajarajan A ^a   Sukumaran, Vijayakumar ^a   Watanabe, Kenichi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN RECEPTOR; ARGIPRESSIN RECEPTOR BLOCKING AGENT; CONIVAPTAN; HORMONE RECEPTOR BLOCKING AGENT; LIXIVAPTAN; LOOP DIURETIC AGENT; SATAVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; HEART FAILURE; HUMAN; HYPONATREMIA; NONHUMAN; RECEPTOR BLOCKING; REVIEW; SINGLE DRUG DOSE; VASOCONSTRICTION;

ARGININE VASOPRESSIN; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEART FAILURE; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 77957671658     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.08.001     Document Type: Review

References (138)

1. Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73:257-267.
2. Baran D., Hutchinson T.A. The outcome of hyponatremia in a general hospital population. Clin. Nephrol. 1984, 22:72-76.
3. Goldsmith S.R. Vasopressin: a therapeutic target in congestive heart failure?. J. Card. Fail. 1999, 5:347-356.
4. Lee C.R., et al. Vasopressin: a new target for the treatment of heart failure. Am. Heart J. 2003, 146:9-18.
5. Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr. Opin. Pharmacol. 2003, 3:683-687.
6. Lilly L.S., et al. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J. Clin. Endocrinol. Metab. 1984, 59:924-930.
7. Oren R.M. Hyponatremia in congestive heart failure. Am. J. Cardiol. 2005, 95:2B-7B.
8. Sica D.A. Hyponatremia and heart failure - treatment considerations. Congest. Heart Fail. 2006, 12:55-60.
9. Naitoh M., et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. 1994, 267:H2245-H2254.
10. Palm C., et al. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc. Res. 2001, 51:403-408.
11. Burrell L.M., et al. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension 1995, 26:828-834.
12. Burrell L.M., et al. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994, 23:737-743.
13. Gattone V.H., et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 2003, 9:1323-1326.
14. Fujisawa G., et al. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int. 1993, 44:19-23.
15. Saito T., et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J. Clin. Endocrinol. Metab. 1997, 82:1054-1057.
16. Bichet D., et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med. 1982, 96:413-417.
17. Lacheretz F., et al. Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension. J. Ocul. Pharmacol. Ther. 2000, 16:203-216.
18. Goldsmith S.R. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am. J. Cardiol. 2005, 95:14B-23B.
19. Hofbauer K.G., et al. Chronic blockade of vasopressin receptors in rats. J. Cardiovasc. Pharmacol. 1986, 8(Suppl. 7):S56-S60.
20. Mah S.C., et al. Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 1988, 245:1021-1027.
21. Nicod P., et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am. J. Cardiol. 1985, 55:1043-1047.
22. Schrier R.W., Martin P.Y. Recent advances in the understanding of water metabolism in heart failure. Adv. Exp. Med. Biol. 1998, 449:415-426.
23. Verbalis J.G. Vasopressin V2 receptor antagonists. J. Mol. Endocrinol. 2002, 29:1-9.
24. Tahara A., et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 1997, 282:301-308.
25. Yatsu T., et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur. J. Pharmacol. 1997, 321:225-230.
26. Tomura Y., et al. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin. Exp. Pharmacol. Physiol. 1999, 26:399-403.
27. Albright J.D., et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem. 1998, 41:2442-2444.
28. Serradeil-Le Gal C., et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. 1996, 98:2729-2738.
29. Yamamura Y., et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 1998, 287:860-867.
30. Schrier R.W., et al. Osmotic and nonosmotic control of vasopressin release. Am. J. Physiol. 1979, 236:F321-F332.
31. Share L. Role of vasopressin in cardiovascular regulation. Physiol. Rev. 1988, 68:1248-1284.
32. Kamoi K., et al. Interaction of osmotic and nonosmotic stimuli in regulation of vasopressin secretion in hypoosmolar state of man. Endocr. J. 1997, 44:311-317.
33. Verbalis J.G. Disorders of body water homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 2003, 17:471-503.
34. Yamaguchi K., et al. Plasma vasopressin response to peripheral administration of angiotensin in conscious rats. Am. J. Physiol. 1985, 248:R249-R256.
35. Yamaguchi K., Yamada T. Involvement of anteroventral third ventricular AMPA/kainate receptors in both hyperosmotic and hypovolemic AVP secretion in conscious rats. Brain Res. Bull. 2006, 71:183-192.
36. Michell R.H., et al. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. 1979, 7:861-865.
37. Birnbaumer M. Vasopressin receptors. Trends Endocrinol. Metab. 2000, 11:406-410.
38. 2+ stores. J. Biol. Chem. 1998, 273:3747-3755.
39. Chandrashekhar Y., et al. The role of arginine vasopressin and its receptors in the normal and failing rat heart. J. Mol. Cell. Cardiol. 2003, 35:495-504.
40. Guyton A.C. The kidneys and body fluids. Text Book of Medical Physiology 1996, 308-372. WB Saunders. A.C. Guyton, J.E. Hall (Eds.).
41. Saito M., et al. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. Eur. J. Pharmacol. 2000, 401:289-296.
42. Folny V., et al. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E566-E576.
43. Nielsen S., et al. Physiology and pathophysiology of renal aquaporins. J. Am. Soc. Nephrol. 1999, 10:647-663.
44. 2O transport in inner medullary collecting duct subsegments. Am. J. Physiol. 1987, 253:F823-F832.
45. Bernat A., et al. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J. Pharmacol. Exp. Ther. 1997, 282:597-602.
46. Francis G.S., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
47. Goldsmith S.R., et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1983, 1:1385-1390.
48. Szatalowicz V.L., et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 1981, 305:263-266.
49. Rouleau J.L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol. 1994, 24:583-591.
50. Nielsen S., et al. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:5450-5455.
51. Xu D.L., et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J. Clin. Invest. 1997, 99:1500-1505.
52. Goldsmith S.R., et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. 1986, 8:779-783.
53. Tahara A., et al. AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors. Pflugers Arch. 1999, 437:219-226.
54. Tahara A., et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur. J. Pharmacol. 1999, 368:89-94.
55. Tahara A., et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc. Res. 1998, 38:198-205.
56. Nakamura Y., et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur. J. Pharmacol. 2000, 391:39-48.
57. Fukuzawa J., et al. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Cell. Biochem. 1999, 195:93-98.
58. Tahara A., et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J. Cardiovasc. Pharmacol. 1997, 30:759-766.
59. Spannheimer A., et al. Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?. Praxis (Bern 1994) 2002, 91:1467-1475.
60. Blose J.S., et al. Torsemide: a pyridine-sulfonylurea loop diuretic. Ann. Pharmacother. 1995, 29:396-402.
61. Friedel H.A., Buckley M.M. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991, 41:81-103.
62. Brater D.C. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996, 14:104-120.
63. López B., et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 2004, 43:2028-2035.
64. Müller K., et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. Eur. J. Heart Fail. 2003, 5:793-801.
65. Cosín J., Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 2002, 4:507-513.
66. Murray M.D., et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am. J. Med. 2001, 111:513-520.
67. Spannheimer A., et al. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int. J. Clin. Pract. 1998, 52:467-471.
68. Kido H., Ohtaki Y. Nippon Yakurigaku Zasshi 2001, 118:97-105.
69. Dunn C.J., et al. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995, 49:121-142.
70. Veeraveedu P.T., et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2008, 75:649-659.
71. Cooper H.A., et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100:1311-1315.
72. Domanski M., et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 2003, 42:705-708.
73. McCurley J.M., et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J. Am. Coll. Cardiol. 2004, 44:1301-1307.
74. Klein L., et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005, 111:2454-2460.
75. Felker G.M., et al. Risk stratification after hospitalization for decompensated heart failure. J. Card. Fail. 2004, 10:460-466.
76. Rossi J., et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care 2007, 9:82-86.
77. Sawyer W.H., Manning M. Synthetic analogs of oxytocin and the vasopressins. Annu. Rev. Pharmacol. 1973, 13:1-17.
78. Sawyer W.H., Manning M. The development of vasopressin antagonists. Fed. Proc. 1984, 43:87-90.
79. Greenberg A., Verbalis J.G. Vasopressin receptor antagonists. Kidney Int. 2006, 69:2124-2130.
80. Creager M.A., et al. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J. Am. Coll. Cardiol. 1986, 7:758-765.
81. Goldsmith S.R., Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol. 2005, 46:1785-1791.
82. Ohnishi A., et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. 1993, 92:2653-2659.
83. Risvanis J., et al. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. Eur. J. Pharmacol. 1999, 381:23-30.
84. Yatsu T., et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur. J. Pharmacol. 1999, 376:239-246.
85. Yatsu T., et al. Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs. Pharmacol. Res. 2002, 46:375-381.
86. Wada K., et al. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur. J. Pharmacol. 2002, 450:169-177.
87. Wada K., et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur. J. Pharmacol. 2005, 507:145-151.
88. Naitoh M., et al. Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc. Res. 2002, 54:51-57.
89. Yamamura Y., et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 1992, 105:787-791.
90. Wong L.L., Verbalis J.G. Vasopressin V2 receptor antagonists. Cardiovasc. Res. 2001, 51:391-402.
91. Miyazaki T., et al. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc. Drug Rev. 2007, 25:1-13.
92. Hirano T., et al. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol. Exp. Ther. 2000, 292:288-294.
93. Kodama M., et al. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin. Immunol. Immunopathol. 1990, 57:250-262.
94. Veeraveedu P.T., et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem. Pharmacol. 2008, 75:1322-1330.
95. Veeraveedu P.T., et al. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. Biochem. Pharmacol. 2007, 74:1466-1475.
96. Onogawa T., et al. Effects of tolvaptan (OPC-41061), a vasopressin V2 receptor antagonist, and furosemide on hemodynamics, renal functions, serum electrolytes, and neurohormones in dogs with and without heart failure. Circulation 2004, 110(Suppl. III):21.
97. Costello-Boerrigter L.C., et al. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ. Heart Fail. 2010, 3:412-419.
98. Miyazaki T., et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 2005, 146:3037-3043.
99. Fujita N., et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am. J. Physiol. 1995, 269:F926-F931.
100. Tsuboi Y., et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 1994, 46:237-244.
101. Ros J., et al. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br. J. Pharmacol. 2005, 146:654-661.
102. Fernández-Varo G., et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J. Hepatol. 2003, 38:755-761.
103. Jiménez W., et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J. Pharmacol. Exp. Ther. 2000, 295:83-90.
104. Fleeman L.M., et al. Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone. Aust. Vet. J. 2000, 78:825-830.
105. Wada K., et al. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol. Pharm. Bull. 2007, 30:91-95.
106. Ishikawa S., Schrier R.W. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats. Kidney Int. 1982, 22:587-593.
107. Saito T., et al. Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats. Am. J. Physiol. Renal Physiol. 2000, 279:F502-F508.
108. Wang W., et al. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Am. J. Physiol. Renal Physiol. 2006, 290:F1135-F1142.
109. Gattone V.H., et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev. Genet. 1999, 24:309-318.
110. Torres V.E., et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 2004, 10:363-364.
111. Torres V.E. Vasopressin antagonists in polycystic kidney disease. Semin. Nephrol. 2008, 28:306-317.
112. Wang X., et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 2005, 16:846-851.
113. Yamaguchi T., et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J. Biol. Chem. 2004, 279:40419-40430.
114. Nagao S., et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J. Am. Soc. Nephrol. 2006, 17:2220-2227.
115. Ghali J.K., et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 2006, 91:2145-2152.
116. Zeltser D., et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol. 2007, 27:447-457.
117. Schrier R.W., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006, 355:2099-2112.
118. Gheorghiade M., et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol. 2006, 97:1064-1067.
119. Berl T., et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol. 2010, 21:705-712.
120. Verbalis J., et al. Novel vasopressin V1a and V2 antagonist (conivaptan) increases serum sodium concentration in patients with hyponatremia secondary to congestive heart failure. J. Card. Fail. 2005, 11(Suppl. 6):S120.
121. Russell S.D., et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. 2003, 145:179-186.
122. Goldsmith S.R., et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J. Card. Fail. 2008, 14:641-647.
123. Tonkon M., et al. Interaction between furosemide and oral conivaptan (YM087) in patients with heart failure. Eur. Heart J. 2001, 22:541.
124. Gheorghiade M., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690-2696.
125. Gheorghiade M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. J. Am. Med. Assoc. 2004, 291:1963-1971.
126. Gheorghiade M., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J. Am. Med. Assoc. 2007, 297:1332-1343.
127. Konstam M.A., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. J. Am. Med. Assoc. 2007, 297:1319-1331.
128. Gheorghiade M., et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail. 2005, 11:260-269.
129. Udelson J.E., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417-2423.
130. Udelson J.E., et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 2008, 52:1540-1545.
131. Udelson J.E., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 2007, 49:2151-2159.
132. Costello-Boerrigter L.C., et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. 2006, 290:F273-F278.
133. Udelson J.E., et al. Acute hemodynamic effects of tolvaptan, a Vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multicenter, randomized, placebo-controlled trial. J. Card. Fail. 2007, 13:793-794.
134. "TEMPO 3/4 Trial" Tolvaptan Efficacy and Safety in Management of Polycystic Kidney Disease and Its Outcomes (TEMPO3/4) (). (accessed 27 October 2009). http://clinicaltrials.gov/ct2/show/NCT00428948.
135. Hunt S.A. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Website. J. Am. Coll. Cardiol. 2005, 46:e1-e82.
136. McMurray J.J., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. J. Am. Med. Assoc. 2007, 298:2009-2019.
137. Mann D.L., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
138. CardioKine Inc. THE BALANCE study: treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation () (accessed 27 October 2009). http://www.clinicaltrials.gov/ct2/show/NCT00578695.